Literature DB >> 1401205

Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms.

I Ramasamy1, M Brisco, A Morley.   

Abstract

AIMS: To develop a simple, optimised, polymerase chain reaction (PCR) based method for detecting the rearranged immunoglobulin heavy chain (IgH).
METHODS: Using as primers oligonucleotides (Fr2A, Fr2B) homologous to the conserved sequences to the framework II region and the joining (JH) region, 25 patients with B cell lymphoproliferative disorders, previously characterised by Southern blotting, and three patients with light chain myeloma were studied.
RESULTS: The PCR product from a polyclonal B cell population showed a broad band when analysed on a 3% agarose gel; DNA from B cell lines and B lymphoproliferative disorders showed a discrete band. Specificity of the amplification was confirmed by cloning and sequencing the amplified product as well as by Southern blotting with an internal probe homologous to the framework 3 region. Primers Fr2A and Fr2B detected monoclonality in three patients with light chain myeloma, while primers directed against the FrIII region showed a polyclonal response.
CONCLUSIONS: Deletions and extensive somatic mutations within the FrIII region may give false negative results with primers homologous to the region. A PCR using the method described, with a repertoire of primers homologous to the FrII and FrIII regions, will therefore increase the frequency of detection of monoclonality.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401205      PMCID: PMC495101          DOI: 10.1136/jcp.45.9.770

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  Determination of lineage and clonality in diffuse lymphomas using the polymerase chain reaction technique.

Authors:  P Lardelli; R F Swaby; L J Medeiros; E S Jaffe; R Rizzi; M Stetler-Stevenson
Journal:  Hum Pathol       Date:  1991-07       Impact factor: 3.466

2.  Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction.

Authors:  K J Trainor; M J Brisco; J H Wan; S Neoh; S Grist; A A Morley
Journal:  Blood       Date:  1991-07-01       Impact factor: 22.113

3.  An improved method for detection of B-lymphoid clonality by polymerase chain reaction.

Authors:  M Deane; K P McCarthy; L M Wiedemann; J D Norton
Journal:  Leukemia       Date:  1991-08       Impact factor: 11.528

4.  Rapid method for distinguishing clonal from polyclonal B cell populations in surgical biopsy specimens.

Authors:  K P McCarthy; J P Sloane; L M Wiedemann
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

5.  Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements.

Authors:  R Grosschedl; D Baltimore
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

6.  Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes.

Authors:  J V Ravetch; U Siebenlist; S Korsmeyer; T Waldmann; P Leder
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

7.  Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes.

Authors:  M Yamada; S Hudson; O Tournay; S Bittenbender; S S Shane; B Lange; Y Tsujimoto; A J Caton; G Rovera
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

8.  Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction.

Authors:  J H Wan; K J Trainor; M J Brisco; A A Morley
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

9.  No detectable malignant B cells in the peripheral blood of patients with multiple myeloma.

Authors:  G Clofent; B Klein; T Commes; N Ghanem; M P Lefranc; R Bataille
Journal:  Br J Haematol       Date:  1989-03       Impact factor: 6.998

10.  Content and organization of the human Ig VH locus: definition of three new VH families and linkage to the Ig CH locus.

Authors:  J E Berman; S J Mellis; R Pollock; C L Smith; H Suh; B Heinke; C Kowal; U Surti; L Chess; C R Cantor
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

View more
  72 in total

1.  Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection.

Authors:  F Fend; L Quintanilla-Martinez; S Kumar; M W Beaty; L Blum; L Sorbara; E S Jaffe; M Raffeld
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Reactive and neoplastic lymphocytes in human bone marrow: morphological, immunohistological, and molecular biological investigations on biopsy specimens.

Authors:  S M Kröber; H P Horny; A Greschniok; E Kaiserling
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

3.  Epstein-Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing.

Authors:  Yasuo Sugita; Mizuhiko Terasaki; Daisuke Niino; Koichi Ohshima; Arakawa Fumiko; Minoru Shigemori; Yasuharu Sato; Naoko Asano
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

4.  Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B cell lymphomas.

Authors:  M Nihal; D Mikkola; G S Wood
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

5.  Development of immunoglobulin variable heavy chain gene consensus probes with conjugated 3' minor groove binder groups for monitoring minimal residual disease in childhood acute lymphoblastic leukaemia.

Authors:  M Uchiyama; C Maesawa; A Yashima; T Itabashi; T Satoh; M Tarusawa; M Endo; Y Takahashi; S Sasaki; S Tsuchiya; Y Ishida; T Masuda
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

6.  Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.

Authors:  Roberto Marasca; Rossana Maffei; Monica Morselli; Patrizia Zucchini; Ilaria Castelli; Silvia Martinelli; Marcella Fontana; Sara Ravanetti; Monica Curotti; Giovanna Leonardi; Katia Cagossi; Giovanni Partesotti; Giuseppe Torelli
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

7.  Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.

Authors:  Michihiro Uchiyama; Chihaya Maesawa; Akiko Yashima-Abo; Mitsu Tarusawa; Mikiya Endo; Waka Sugawara; Shoichi Chida; Shima Onodera; Yasuhiko Tsukushi; Yoji Ishida; Shigeru Tsuchiya; Tomoyuki Masuda
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

8.  IgH PCR of zinc formalin-fixed, paraffin-embedded non-lymphomatous gastric samples produces artifactual "clonal" bands not observed in paired tissues unexposed to zinc formalin.

Authors:  Kim Ahrens; Raul Braylan; Nidal Almasri; Robin Foss; Lisa Rimsza
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

9.  Consensus primers for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell lymphomas.

Authors:  M Uchiyama; C Maesawa; A Yashima; T Itabashi; Y Ishida; T Masuda; T Maesawa
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

10.  EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Authors:  Deirdre O'Mahony; John C Morris; Maryalice Stetler-Stevenson; Helen Matthews; Margaret R Brown; Thomas Fleisher; Stefania Pittaluga; Mark Raffeld; Paul S Albert; Dirk Reitsma; Karen Kaucic; Luz Hammershaimb; Thomas A Waldmann; John E Janik
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.